分子生物标志物在膀胱癌检测中的临床应用重要性。
The importance of clinical application of molecular biomarkers in bladder cancer detection.
作者信息
Dumache Raluca, Puiu Maria, David Dana, Popovici Marinela, Kaycsa Adriana, Negru Serban, Miclea Florin
机构信息
Department of Biochemistry, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
出版信息
Maedica (Bucur). 2010 Apr;5(2):124-7.
Abstract
It is known that high throughput technologies facilitate the identification of new molecular targets and biomarkers specific for bladder cancer.The new field of molecular medicine promises that clinical outcomes will be improved by directing therapy toward the molecular mechanisms and targets associated with the growth of the patient's tumor.The great challenge remains to improve the measurement of these targets and to translate this wealth of discovery into clinical management of bladder cancer.
摘要
众所周知，高通量技术有助于识别膀胱癌特有的新分子靶点和生物标志物。分子医学的新领域有望通过针对与患者肿瘤生长相关的分子机制和靶点进行治疗来改善临床结果。巨大的挑战仍然是改进这些靶点的检测，并将这一丰富的发现转化为膀胱癌的临床管理。
相似文献
1
The importance of clinical application of molecular biomarkers in bladder cancer detection.
Maedica (Bucur). 2010 Apr;5(2):124-7.
2
ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers.
Eur Urol. 2013 Jan;63(1):4-15. doi: 10.1016/j.eururo.2012.09.057. Epub 2012 Oct 4.
3
Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer.
Clin Chem. 2003 Jan;49(1):23-31. doi: 10.1373/49.1.23.
4
Biomarkers in bladder cancer: present status and perspectives.
Biomark Insights. 2007 Mar 27;2:95-105.
5
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
J Natl Cancer Inst. 2006 Jul 19;98(14):996-1004. doi: 10.1093/jnci/djj265.
6
Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation.
Eur Urol Focus. 2020 Jul 15;6(4):683-697. doi: 10.1016/j.euf.2019.02.012. Epub 2019 Feb 23.
7
New cancer biomarkers deriving from NCI early detection research.
Recent Results Cancer Res. 2003;163:72-84; discussion 264-6. doi: 10.1007/978-3-642-55647-0_7.
8
Multiplexed methylation profiles of tumor suppressor genes in bladder cancer.
J Mol Diagn. 2011 Jan;13(1):29-40. doi: 10.1016/j.jmoldx.2010.11.008. Epub 2010 Dec 23.
9
Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel.
Clin Cancer Res. 2004 Mar 15;10(6):1887-93. doi: 10.1158/1078-0432.ccr-03-0127.
10
Molecular alterations associated with bladder cancer progression.
Semin Oncol. 2007 Apr;34(2):75-84. doi: 10.1053/j.seminoncol.2006.12.013.
本文引用的文献
1
Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
J Urol. 2007 Feb;177(2):481-7; discussion 487. doi: 10.1016/j.juro.2006.09.038.
2
Urothelial tumorigenesis: a tale of divergent pathways.
Nat Rev Cancer. 2005 Sep;5(9):713-25. doi: 10.1038/nrc1697.
3
Telomerase activity in urine sediments as a tool for noninvasive detection of bladder cancer.
Cancer Lett. 2005 May 10;222(1):83-8. doi: 10.1016/j.canlet.2004.09.004.
4
Cancer epigenetics.
Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R65-76. doi: 10.1093/hmg/ddi113.
5
Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
J Clin Oncol. 2005 May 1;23(13):2903-10. doi: 10.1200/JCO.2005.03.163. Epub 2005 Mar 7.
6
Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
Urology. 2004 Jun;63(6):1079-83. doi: 10.1016/j.urology.2004.01.009.
7
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
J Clin Oncol. 2004 Mar 15;22(6):1007-13. doi: 10.1200/JCO.2004.05.174. Epub 2004 Feb 23.
8
The health economics of bladder cancer: a comprehensive review of the published literature.
Pharmacoeconomics. 2003;21(18):1315-30. doi: 10.1007/BF03262330.
9
Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder.
Urology. 2003 Jun;61(6):1140-5. doi: 10.1016/s0090-4295(03)00236-x.
10
Loss of heterozygosity on chromosome 5p13-12 predicts adverse prognosis in advanced bladder cancer independent of tumor stage and grade.
J Urol. 2002 Dec;168(6):2655-8. doi: 10.1016/S0022-5347(05)64238-3.
Zotero 插件